AEterna Zentaris (AEZS) to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Tweet Send to a Friend
AEterna Zentaris Inc. (NASDAQ: AEZS) reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
